Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 10:24 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1473 of 1,473 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Safety Testing Clear all
Terminated Phase 2 Interventional Results available

To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF

NCT05497284
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
LTP001, Placebo, Standard of Care (SoC)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 100 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Birmingham, Alabama • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Nov 2, 2026, 10:24 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Adults to Evaluate the Bioavailability of Two Test Tablet Formulations of ABT-450

NCT01091649
View directory record Official record
Conditions
Healthy
Interventions
ABT-450, ritonavir
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Waukegan, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 21, 2010 · Synced Nov 2, 2026, 10:24 AM EST
Terminated Phase 1 Interventional Results available

Insulin Tolerance Test Study in Patients With Type 1 Diabetes

NCT04026750
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia
Interventions
Pitolisant
Drug
Lead sponsor
High Point Clinical Trials Center
Industry
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Nov 2, 2026, 10:24 AM EST
Recruiting Phase 1Phase 2 Interventional

Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

NCT06680752
View directory record Official record
Conditions
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, MDS (Myelodysplastic Syndrome)
Interventions
ARD103, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
ARCE Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Charlotte, North Carolina • Winston-Salem, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Nov 2, 2026, 10:24 AM EST
Active, not recruiting Phase 1 Interventional

DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy

NCT05990738
View directory record Official record
Conditions
Small Cell Lung Carcinoma (SCLC)
Interventions
BI 764532, Topotecan, Single agent chemotherapy
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Jacksonville, Florida • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Nov 2, 2026, 10:24 AM EST
Terminated Phase 1 Interventional Results available

A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

NCT04422210
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Venetoclax, Atezolizumab, Carboplatin, Etoposide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Nov 2, 2026, 10:24 AM EST
Completed Not applicable Interventional

Improving Exercise Capacity With Tailored Physical Activity in Lymphoma & Breast Cancer Patients Undergoing Tx

NCT03923504
View directory record Official record
Conditions
Hodgkin Lymphoma, Non-hodgkin Lymphoma, Lymphoma, Breast Cancer
Interventions
Physical Activity Intervention (PAI), Healthy Living Control
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Richmond, Virginia • South Hill, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Nov 2, 2026, 10:24 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study to Assess AER-271

NCT03804476
View directory record Official record
Conditions
Stroke, Stroke, Acute, Stroke, Ischemic
Interventions
AER-271, Placebo
Drug
Lead sponsor
Aeromics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Nov 2, 2026, 10:24 AM EST
Terminated Phase 3 Interventional Results available

A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

NCT03739840
View directory record Official record
Conditions
Drug-Resistant Epilepsy, Focal-Onset Seizures
Interventions
Padsevonil, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
32
States / cities
Chandler, Arizona • Tucson, Arizona • Carlsbad, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Nov 2, 2026, 10:24 AM EST